A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C Adeno-Associated Virus Vaccine-Reference-Cited by-同舟云学术

A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C Adeno-Associated Virus Vaccine

Published:2008-06 Issue:6 Volume:24 Page:873-880
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Mehendale Sanjay¹,van Lunzen Jan²,Clumeck Nathan³,Rockstroh Jurgen⁴,Vets Eva⁵,Johnson Philip R.⁶,Anklesaria Pervin⁷,Barin Burc⁸,Boaz Mark⁹,Kochhar Sonali¹⁰,Lehrman Jennifer¹¹,Schmidt Claudia¹¹,Peeters Mathieu⁵,Schwarze-Zander Carolynne⁴,Kabamba Kabeya³,Glaunsinger Tobias²,Sahay Seema¹,Thakar Madhuri¹,Paranjape Ramesh¹,Gilmour Jill⁹,Excler Jean-Louis¹⁰,Fast Patricia¹¹,Heald Alison E.⁷

Affiliation:

1. National AIDS Research Institute, Pune, India.

2. University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

3. St. Pierre University Hospital, Brussels, Belgium.

4. University Clinic, Bonn, Germany.

5. SGS Biopharma, Antwerp, Belgium.

6. The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 and Columbus Children's Research Institute, Columbus, Ohio 43205.

7. Targeted Genetics Corporation, Seattle, Washington 98101.

8. EMMES Corporation, Rockville, Maryland 20850.

9. International AIDS Vaccine Initiative, Core Laboratory, London, UK.

10. International AIDS Vaccine Initiative, New Delhi, India.

11. International AIDS Vaccine Initiative, New York, New York 10038.